Melatonin is a potential inhibitor of ovarian cancer: molecular aspects
Abstract Ovarian cancer is one of the most common causes of morbidity related to gynecologic malignancies. Possible risk factors are including hereditary ovarian cancer, obesity, diabetes mellitus, alcohol consumption, aging, and smoking. Various molecular signaling pathways including inflammation,...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13048-019-0502-8 |
id |
doaj-6ed3603ec4d241798f5ebd25f27aa2c1 |
---|---|
record_format |
Article |
spelling |
doaj-6ed3603ec4d241798f5ebd25f27aa2c12020-11-25T03:35:56ZengBMCJournal of Ovarian Research1757-22152019-03-011211810.1186/s13048-019-0502-8Melatonin is a potential inhibitor of ovarian cancer: molecular aspectsHadis Zare0Rana Shafabakhsh1Russel J. Reiter2Zatollah Asemi3Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical SciencesResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical SciencesDepartment of Cellular and Structural Biology, University of Texas Health Science, CenterResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical SciencesAbstract Ovarian cancer is one of the most common causes of morbidity related to gynecologic malignancies. Possible risk factors are including hereditary ovarian cancer, obesity, diabetes mellitus, alcohol consumption, aging, and smoking. Various molecular signaling pathways including inflammation, oxidative stress, apoptosis and angiogenesis are involved in this progression of ovarian cancer. Standard treatments for recently diagnosed patients are Surgery and chemotherapy such as co-treatment with other drugs such that the exploitation of neoadjuvant chemotherapy is expanding. Melatonin (N-acetyl-5-methoxy-tryptamine), an endogenous agent secreted from the pineal gland, has anti-carcinogenic features, such as regulation of estradiol production, cell cycle modulation, stimulation of apoptosis as well as anti-angiogenetic properties, anti-inflammatory activities, significant antioxidant effects and modulation of various immune system cells and cytokines. Multiple studies have shown the significant beneficial roles of melatonin in various types of cancers including ovarian cancer. This paper aims to shed light on the roles of melatonin in ovarian cancer treatment from the standpoint of the molecular aspects.http://link.springer.com/article/10.1186/s13048-019-0502-8MelatoninOvarian cancerSignaling pathwaysAnti-inflammatory activitiesAnti-angiogenetic properties |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hadis Zare Rana Shafabakhsh Russel J. Reiter Zatollah Asemi |
spellingShingle |
Hadis Zare Rana Shafabakhsh Russel J. Reiter Zatollah Asemi Melatonin is a potential inhibitor of ovarian cancer: molecular aspects Journal of Ovarian Research Melatonin Ovarian cancer Signaling pathways Anti-inflammatory activities Anti-angiogenetic properties |
author_facet |
Hadis Zare Rana Shafabakhsh Russel J. Reiter Zatollah Asemi |
author_sort |
Hadis Zare |
title |
Melatonin is a potential inhibitor of ovarian cancer: molecular aspects |
title_short |
Melatonin is a potential inhibitor of ovarian cancer: molecular aspects |
title_full |
Melatonin is a potential inhibitor of ovarian cancer: molecular aspects |
title_fullStr |
Melatonin is a potential inhibitor of ovarian cancer: molecular aspects |
title_full_unstemmed |
Melatonin is a potential inhibitor of ovarian cancer: molecular aspects |
title_sort |
melatonin is a potential inhibitor of ovarian cancer: molecular aspects |
publisher |
BMC |
series |
Journal of Ovarian Research |
issn |
1757-2215 |
publishDate |
2019-03-01 |
description |
Abstract Ovarian cancer is one of the most common causes of morbidity related to gynecologic malignancies. Possible risk factors are including hereditary ovarian cancer, obesity, diabetes mellitus, alcohol consumption, aging, and smoking. Various molecular signaling pathways including inflammation, oxidative stress, apoptosis and angiogenesis are involved in this progression of ovarian cancer. Standard treatments for recently diagnosed patients are Surgery and chemotherapy such as co-treatment with other drugs such that the exploitation of neoadjuvant chemotherapy is expanding. Melatonin (N-acetyl-5-methoxy-tryptamine), an endogenous agent secreted from the pineal gland, has anti-carcinogenic features, such as regulation of estradiol production, cell cycle modulation, stimulation of apoptosis as well as anti-angiogenetic properties, anti-inflammatory activities, significant antioxidant effects and modulation of various immune system cells and cytokines. Multiple studies have shown the significant beneficial roles of melatonin in various types of cancers including ovarian cancer. This paper aims to shed light on the roles of melatonin in ovarian cancer treatment from the standpoint of the molecular aspects. |
topic |
Melatonin Ovarian cancer Signaling pathways Anti-inflammatory activities Anti-angiogenetic properties |
url |
http://link.springer.com/article/10.1186/s13048-019-0502-8 |
work_keys_str_mv |
AT hadiszare melatoninisapotentialinhibitorofovariancancermolecularaspects AT ranashafabakhsh melatoninisapotentialinhibitorofovariancancermolecularaspects AT russeljreiter melatoninisapotentialinhibitorofovariancancermolecularaspects AT zatollahasemi melatoninisapotentialinhibitorofovariancancermolecularaspects |
_version_ |
1724552321756561408 |